Skip to content
MarketScale
‹ Back to IndustriesSciences

How Freezing Temperatures Became the Hottest Trend in Wellness

The beauty industry is an economic gold mine and consumers are on a constant journey of exploration. One practice in particular, cryotherapy, has continued to defy conventional wisdom within the anti-aging and weight loss industry. The emerging method has both women and men pouring money into this cutting-edge wellness movement. What began as a pain…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Ally Shay · Ally Shay ArticleCryoCryotherapyHealth
Share
How Freezing Temperatures Became the Hottest Trend in Wellness

Key takeaways

01

The beauty industry is an economic gold mine and consumers are on a constant journey of exploration.

02

One practice in particular, cryotherapy, has continued to defy conventional wisdom within the anti-aging and weight loss industry.

03

The emerging method has both women and men pouring money into this cutting-edge wellness movement.

The beauty industry is an economic gold mine and consumers are on a constant journey of exploration. One practice in particular, cryotherapy, has continued to defy conventional wisdom within the anti-aging and weight loss industry. The emerging method has both women and men pouring money into this cutting-edge wellness movement.

What began as a pain management tool and treatment for cancers, dementia and other illnesses, has transformed into an increasingly popular health craze.

The Science Behind the Craze

Cryotherapy is the process of subjecting the body to temperatures of up to -200 degrees Fahrenheit for around three minutes in a localized chamber. Physiologically, the change in temperature triggers a fight or flight response, forcing the body to enrich the organs with oxygen and increase circulation in an attempt to survive.

In 2015, the global cryotherapy market accounted for $2.5 billion and is projected to grow at a compound annual growth rate of 9.7% during a forecast period that continues to 2024, according to Grandview Research.

The cosmetic results of the process have been known to reduce cellulite, kick-start the metabolism, increase collagen production that reduces wrinkles and tighten pores. It has even been shown to release endorphins due to a Zen-like feeling that comes when the brain is forced into a heightened state, desperate for subsistence.

The extremes we go to for beauty, right?

Warming up to Change

While a lot of industries are hesitant to introduce change and risk breaking consumer routines, beauty and wellness is not one of them.

President and CEO of Shiseido Americas Marc Rey highlighted in an interview with Forbes that traditional makeup sales were down 1.3% in 2016, but independent brands were up 42.7%. This industry is a rare one in the sense that consumers are not only open to change, but often want to be the first to embrace it. Trends that begin as “hole in the wall” businesses like cryotherapy attract a fresh demographic and the growth of these types of corporations represent just how receptive consumers are to change.

While the more superficial benefits have yielded an incredible market, the medical-centric consumers back research adequate to warrant transforming oneself into a human icicle.

The chamber freezes abnormal tissue which can be attributed to killing certain cancers. The freezing conditions act as an ice bath taken to an extreme which helps aches, pains, muscle recovery and arthritis. Other medical benefits include migraine treatment, and the anti-inflammatory and oxidative stress process has even been known to help treat Alzheimer’s disease and Dementia.

Is the Freeze a Fad?

From a business standpoint, consumer behavior in response to a trend is not necessarily a telling factor of how the future of an industry will perform. However, consider this statement: no pain, no gain. We as consumers have translated this saying into our health, beauty and overall attitude about wellness. As technology and science continue to manifest new ways to achieve beauty, consumers have raised expectations on results.

In other words, if we were suddenly expected to fetch our water from a river and manually purify it, filling the Brita would not seem so arduous. Consumers are more and more willing to try new trends as the number of opportunities or services themselves increase.

While certain fads are important in how businesses adapt, they are not dependent on dynamic consumer behavior but rather on this overarching theme that combines millennials’ expectations with subjection to science experiments of their own volition. Cryotherapy is no exception.

Participating in trends allows consumers to feel like they are fully utilizing this science and technology. While Cryo might seem drastic compared to conventional methods of weight loss or anti-aging, this is the reality in how the beauty industry has evolved, and corporations have every right to capitalize on it in hopes of remaining relevant in a rapidly changing market.

About the author

AS
Ally Shay

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

The pharmaceutical industry is facing a significant challenge as over $300 billion in branded pharmaceutical revenue is set to lose patent protection by 2030. This revenue gap is driving the largest merger and acquisition cycle seen in a decade, with companies seeking external growth through acquisitions. This shift is impacting the entire life sciences supply chain, prompting strategic changes across the industry.

  • 01Over $300 billion in pharmaceutical revenue is at risk due to patent expirations by 2030.
  • 02Big Pharma is engaging in an aggressive cycle of mergers and acquisitions.
  • 03The acquisitions are reshaping the life sciences supply chain.

Jun 29, 2026

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences has initiated a Phase I clinical study at its UK facility for an oral solid dose formulation designed using artificial intelligence — what the company believes is the first AI-formulated drug to reach human clinical evaluation. The study, cleared by the UK's Medicines and Healthcare products Regulatory Agency, will assess safety and pharmacokinetics in healthy volunteers. The program, which used Intrepid Labs' machine learning algorithm, signals a broader shift in how contract drug development organizations are integrating AI across formulation and clinical workflows.

  • 01Quotient Sciences initiated a Phase I study of an AI-designed oral solid dose formulation at its UK facility following MHRA approval — the first such case the company believes has been reported.
  • 02The formulation was developed using Intrepid Labs' advanced machine learning algorithm in combination with Quotient Sciences' Translational Pharmaceutics platform.
  • 03The milestone is part of a broader CRDMO strategy to embed AI-enabled approaches across formulation development and clinical workflows, with implications for the wider contract pharma sector.

Jun 17, 2026

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences has initiated a Phase I clinical study of an oral solid dose formulation designed using AI, cleared by the UK's MHRA and conducted at the company's UK facility. The trial—built on machine learning algorithms from partner Intrepid Labs and Quotient's Translational Pharmaceutics platform—aims to validate AI as a direct contributor to formulation design rather than just an upstream analytical tool. Benchling characterizes the broader moment as biotech entering a "builder phase," in which leading organizations embed AI capability at the bench level rather than running isolated pilots.

  • 01Quotient Sciences has dosed healthy volunteers in a Phase I study it describes as the first clinical evaluation of an AI-designed oral formulation, following approval from the UK's MHRA.
  • 02The formulation was developed using advanced machine learning algorithms from Intrepid Labs, integrated with Quotient Sciences' Translational Pharmaceutics platform.
  • 03Benchling identifies a sector-wide shift toward embedding AI capability directly at the bench, moving beyond isolated pilots to structural adoption across biotech R&D.

Jun 17, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

AS
Ally Shay

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512